Mahesh Karande, Omega Therapeutics CEO

Omega Ther­a­peu­tic­s' epige­nom­ic med­i­cines re­duce MYC ex­pres­sion by 55% in ear­ly study of can­cer pa­tients

Omega Ther­a­peu­tics, a com­pa­ny de­sign­ing ge­net­ic med­i­cines that di­al the out­put of genes up or down, on Tues­day morn­ing re­vealed the first da­ta from a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.